PMOS Explained: Why PCOS Has Officially Been Renamed
For years, many women diagnosed with PCOS have had the same experience.
Confusion.
Dismissal.
Symptoms that did not seem to “fit” the name.
Because despite being called polycystic ovary syndrome, the condition was never just about ovaries. And it was never really about “cysts” either.
Now, after an international consensus process involving researchers, clinicians, patient organisations, and thousands of people living with the condition, PCOS has officially been renamed:
Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The new terminology was published in The Lancet in May 2026, and honestly, the change has been a long time coming.
The Problem With the Name “PCOS”
The term polycystic ovary syndrome has been criticised for years as inaccurate and misleading.
One of the biggest issues is that many women with PCOS do not actually have ovarian cysts. The “cysts” referred to in the name are typically immature ovarian follicles, not pathological cysts in the traditional sense.
At the same time, the condition can affect far more than the ovaries.
PCOS can involve insulin resistance, androgen excess, irregular ovulation, acne, hair thinning or unwanted hair growth, fatigue, cravings, fertility challenges, metabolic dysfunction, inflammation, and mental health impacts.
Yet none of that is reflected in the name itself.
For many people, the old terminology reduced a complex, multisystem condition down to one ovarian feature. And not even an entirely accurate one.
Why PMOS?
The new name aims to better reflect what research has increasingly shown over the past two decades: this is not simply a reproductive condition.
It is a condition involving multiple interacting hormonal and metabolic systems.
The term polyendocrine reflects the involvement of multiple endocrine pathways, including insulin signalling, androgen production, ovarian hormones, and neuroendocrine regulation.
Metabolic recognises the major metabolic component of the condition, including insulin resistance, glucose metabolism, cardiovascular risk, and energy regulation.
And ovarian acknowledges that ovarian function still plays a central role, particularly regarding ovulation, follicle development, hormone production, and menstrual cycle changes.
Together, the new name gives a broader and more biologically accurate picture of the condition.
More Than a Rename
What makes this particularly interesting is what it says about women’s health more broadly.
Historically, many conditions affecting women have been oversimplified, misunderstood, or narrowly framed.
PMOS is a good example of that.
For years, patients and researchers have argued that the term PCOS:
reinforced misconceptions
contributed to delayed diagnosis
oversimplified treatment approaches
focused too heavily on fertility
failed to capture the metabolic and endocrine aspects of the condition
contributed to stigma
Teede et al. note that up to 70% of affected individuals may remain undiagnosed.
That is enormous.
And when a condition is poorly understood, people are often left trying to make sense of symptoms that feel disconnected. Irregular cycles, skin changes, fatigue, cravings, weight fluctuations, hair loss, and mood changes can all seem unrelated, when in reality many may be interconnected through shared hormonal and metabolic pathways.
Research increasingly shows that PMOS is genetically, hormonally, and metabolically complex. There is no single “PMOS patient”.
Some women primarily experience cycle irregularities. Others struggle more with metabolic symptoms. Others experience acne, hair changes, fertility challenges, or fatigue.
Importantly, not all women with PMOS fit outdated stereotypes around body size or appearance.
That is one reason the term “metabolic” is so important in the new name. It acknowledges that insulin signalling and metabolism are central parts of the condition, not secondary features.
Will People Still Say PCOS?
For now, yes.
The authors outline a planned transition period of around three years while healthcare systems, guidelines, research databases, education materials, and disease classifications adapt.
Many organisations will likely use:
“PMOS (formerly PCOS)”
This helps maintain clarity while awareness grows around the new terminology.
Realistically, PCOS will probably remain the more recognised search term for some time.
Why Language in Medicine Matters
It can be tempting to see this as “just a rename”.
But medical language shapes awareness, diagnosis, research priorities, policy, funding, stigma, and patient experience.
When the name of a condition fails to reflect the biology accurately, it can influence how seriously symptoms are taken and how care is approached.
The shift from PCOS to PMOS reflects a broader movement in women’s health towards more accurate science, more complete care, and better recognition of the complexity of female biology.
And that matters.
For many women, the old name never fully explained what they were experiencing in the first place.
